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Introduction
Assays that detect anti-citrullinated peptides antibodies
(ACPA) are considered to be more specific than rheu-
matoid factor in the diagnosis of rheumatoid arthritis
(RA). Several tests have been developed using different
antigens: first, second and third-generation cyclic-ACPA
(CCP1, CCP2, CCP3) and modified citrullinated vimen-
tin (MCV).
Aim
To investigate anti-CCP3 in a group of patients positive
citrullinated vimentin antibodies (MCVA).
Patients and methods
A total of 259 patients positive for IgG MCVA+ attend-
ing the outpatient rheumatology clinic of a single gen-
eral hospital (HUGTiP) were tested for anti-CCP3 (by
ELISA). From the total, 182 (70.3%) of them had a rheu-
matic disease (RD): RA in 121 (66.5%) and other RDs in
61 (33.5%). 77 (29.7%) patients with other conditions
positive for MCVA were also tested for anti-CCP3.
Results
From the 121 RA patients, 106 (87.6%) were positive for
anti-CCP3. In contrast, only 15 (24.6%) of the 61
patients without RA and only 4 (5.2%) of the 77 MCVA
+ patients with no RD associated were CCP3 positive.
Interestingly, within the group no RA, of the 13 patients
with anti-CCP3 values >60 U/ml, 6 (46.2%) were cases
of palindromic rheumatism and two of them had devel-
oped RA. Specificity of anti-CCP3 for RA as compared
to other RDs was 76.7%, that raised to 86.9% when com-
paring RA versus to non-RA (with or without another
RDs). Positive and negative predictive values (PPV,
NPV) of anti-CCP3 for RA were 85.5% and 88.8%,
respectively whereas PPV for anti-MCV was 39.1%.
Conclusions
Anti-CCP3 antibodies show a higher specificity for RA
when compared to MCVA with a better PPV, a crucial
feature for a test in use for clinical practice.
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